Preventing tricuspid regurgitation during pacemaker lead implantation
Official title: Prevention of Pacemaker Lead Induced Tricuspid regurgitAtion by Transesophageal eCho guidEd Implantation (PLACE)
Run by LMU Klinikum · NCT05667519 · Data updated 2026-11-12
This study is testing if using a special ultrasound during pacemaker lead placement can help prevent heart valve problems compared to just using X-rays.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 324 (estimated) |
| Sponsor | LMU Klinikum Academic / other |
| Locations | 1 site (Munich, Bavaria) |
| Status | Recruiting |
| Started | October 1, 2022 |
| Main results expected | October 2027 |
| Study ends | October 2027 |
| Registry record updated | December 28, 2022 |
| Trial ID | NCT05667519 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients who require right ventricular lead implantation according to current medical guidelines.
✕Probably not a fit
Patients with preexisting tricuspid regurgitation of grade 2 or higher or other severe heart valve diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial compares two methods of guiding pacemaker lead implantation: one using transesophageal echocardiography combined with fluoroscopy, and the other using fluoroscopy alone. Patients will be randomly assigned to one of the two groups and monitored for up to three years to assess the incidence of lead-induced tricuspid regurgitation. The study aims to determine if the echocardiography-guided approach can reduce complications associated with pacemaker implantation. The primary endpoint will be evaluated by a blinded echocardiographer following established guidelines.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of tricuspid regurgitation and improve outcomes for patients undergoing pacemaker implantation.
How similar studies have gone: Previous studies have suggested that transesophageal echocardiography may reduce complications, but this is the first randomized controlled trial to directly compare these two methods.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * indication for right ventricular lead implantation according to current guidelines Exclusion Criteria: * preexisting tricuspid regurgitation ≥ grade 2 * other severe heart valve disease * history of tricuspid valve treatment * preexisting right ventricular lead * chronic dialysis * contraindication for transesophageal echocardiography
Where it's running
-
LMU Klinikum
Munich, Bavaria, Germany Recruiting
Study contacts
- Principal investigator: Daniel Braun, MD — LMU Klinikum
- Study coordinator: Daniel Braun, MD
- Email: daniel.braun@med.uni-muenchen.de
- Phone: +4989440072371
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
3D Echocardiography to See How CIEDs May Worsen Tricuspid Regurgitation
This study tests whether different CIEDs (leadless pacemakers, LBBaP, and conventional pacemakers) differ in causing worsening tricuspid regurgitation, using 3D heart imaging.
-
Compare leadless and left bundle branch pacemakers for heart and valve function
This study tests whether leadless pacemakers or left bundle branch area pacing better preserve heart and tricuspid valve function in adults needing a pacemaker.
-
TriClip for treating tricuspid regurgitation in Japan
This study will see if the TriClip device is safe and helps people in Japan with symptomatic severe tricuspid regurgitation when used in routine clinical care.
-
Impact of transcatheter tricuspid valve repair on kidneys, strength, and activity in older adults
This study will try catheter-based tricuspid valve repair (TEER) in older adults with severe symptomatic tricuspid regurgitation to see if kidney function, fluid overload, and physical activity improve.
-
TARGET 2.0: Cardiovalve TR replacement for tricuspid regurgitation
This study will test a percutaneously delivered Cardiovalve tricuspid replacement via the femoral vein in adults with symptomatic severe secondary tricuspid regurgitation who are high risk for open-heart surgery.
-
Pivot Extend device to treat severe tricuspid regurgitation
This trial will try the Pivot Extend device in adults with severe, symptomatic tricuspid regurgitation to see if it safely reduces valve leakage and improves symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.